Armenia vs Cameroon: Average cost of multi drug-resistant tuberculosis treatment
Armenia
2,970 constant 2022 US$
in 2024
Cameroon
2,825 constant 2022 US$
in 2024
Armenia rank
16th
Cameroon rank
17th
Average cost of multi drug-resistant tuberculosis treatment over time
- Armenia
- Cameroon
How they compare
Armenia currently reports 2,970 constant 2022 US$ against 2,825 constant 2022 US$ in Cameroon, a difference of 145 constant 2022 US$.
That makes Armenia's figure about 1.1 times Cameroon's.
Across all 6 years both countries report, Armenia has been ahead every year.
Armenia ranks 16th and Cameroon ranks 17th of 92 countries.
Armenia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Armenia | Cameroon | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,850 constant 2022 US$ | 1,035 constant 2022 US$ | 3,815 constant 2022 US$ | Armenia |
| 2020s | 4,196 constant 2022 US$ | 864.4 constant 2022 US$ | 3,332 constant 2022 US$ | Armenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Armenia or Cameroon?
- Armenia, at 2,970 constant 2022 US$ against 2,825 constant 2022 US$ in Cameroon as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Armenia and Cameroon?
- 145 constant 2022 US$, with Armenia ahead.
- How many years of comparable data are there for Armenia and Cameroon?
- 6 years are reported by both, from 2019 to 2024.
- How do Armenia and Cameroon rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Armenia ranks 16th and Cameroon ranks 17th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.